SHCSotera Health Company
Is the business good?
The checks split: nothing decisive, though returns that lean on debt.
Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.
Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.
Leverage-amplified, a high assets-to-equity ratio does much of the work. ROE 17% = margin × turnover × leverage.
Unless marked, from derived.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is SHC?
Sotera Health Company keeps 13% of every revenue dollar as profit after everything, against 3.6% for the median Diagnostics & Research name.
Net margin · Diagnostics & Research median 3.6% · 12 months to Q2 2026
- Share count, year on year
- +0.84%
Share count, year on year · flat: no meaningful dilution
- Gross margin
- 55%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | 25% |
| FY2021 | 28% |
| FY2022 | 25% |
| FY2023 | 26% |
| FY2024 | 27% |
Details›
- Gross margin12 months to Q2 2026
- 55%
- Net margin12 months to Q2 2026
- 13%
- Free cash flow margin
- 9.3%
- Revenue, trailing twelve months
- $1.22B
- Free cash flow, trailing twelve months
- $113M
- Net income, trailing twelve months
- $163M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Diagnostics & Research
Ranks #4 of 21 by RyuScore